pet-ctevaluationoflymphoma.ppt

* * * * * * * * * * * * * * * * * Stage IIA classic nodular sclerosing with complete response after 3rd midtreatment cycle evaluation; 22 yo with mono monospot+ 1 yr ago with enlarging r neeck mass * * * * * * * * * * 65 yr old with pancreatic/renal NH lymphoma and complete therapy response after rituxan, cytoxan prednisone * * * * * * * * * * * * * * Natural killer nasal and nasal type TCL Aggressive lesion Strong association with EBV Variably FDG avid Enteropathy-type TCL Affected patients typically have a history of gluten-sensitive enteropathy and the disorder carries a poor prognosis FDG PET is more sensitive than CT 65 yo female presented with early satiety and nausea Complete response to R-EPOCH 29 yo old female with enlarging thyroid for 1 yr, with bilateral vocal cord paralysis Referred for RAI ablation, but 3 hr uptake was 0.8% and 24 hr uptake was 0.5% Patient underwent subtotal thyroidectomy where lymphoma was discovered Staging PET/CT shows FDG avid adenopathy neck, chest abdomen, pelvis with nonspecific FDG avid consolidation 26 yo old male relapsed after 4 cycles chemo about 5-6 months after presentation Originally presented with rib pain, SOB, fatigue Initially responded well to chemo with resolution of effusion and FDG uptake shortly after chemo started Status post R-EPOCH x 7 with XRT FDG-PET/CT shows no significant activity despite some residual soft tissue Mildly elevated marrow, likely from chemo and/or anemia 66 yo male with ulcerative perianal lesion Pathology revealed EBV positivity No spread of disease at staging Complete response to RCHOP and will be scheduled for involved-field XRT Lung, marrow, nodal involvement Stage 4 NHL Large Cell Lymphoma with gastric, hepatic disease Spleen and marrow uptake has DDX cytokine effect vs. disease involvement Bone-marrow response to G-CSF decreases rapidly following the last CSF administration. Therefore, FDG-PET in patients receiving G-CSF should be delayed, when possible,